LEADER 00969nam0 22002653i 450 001 VAN0252573 005 20221118123839.265 010 $a978-88-317-1788-5 100 $a20221118d2014 |0itac50 ba 101 $aita 102 $aIT 105 $a|||| ||||| 200 1 $aNeorealismo$eil nuovo cinema del dopoguerra$fStefania Parigi 210 $aVenezia$cMarsilio$d2014 215 $a365 p.$d22 cm 410 1$1001VAN0058689$12001 $aBiblioteca$1210 $aVenezia$cMarsilio. 620 $dVenezia$3VANL000080 700 1$aParigi$bStefania$3VANV205799$0527535 712 02$aMarsilio$3VANV108180 801 $aIT$bSOL$c20221125$gRICA 899 $aBIBLIOTECA DEL DIPARTIMENTO DI LETTERE E BENI CULTURALI$1IT-CE0103$2VAN07 912 $aVAN0252573 950 $aBIBLIOTECA DEL DIPARTIMENTO DI LETTERE E BENI CULTURALI$d07CONS Qb 1630 $e07UBL2669 20221118 996 $aNeorealismo$91078221 997 $aUNISOB LEADER 04740nam 2200613z- 450 001 9910163538103321 005 20210211 035 $a(CKB)3710000001048138 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/49986 035 $a(oapen)doab49986 035 $a(EXLCZ)993710000001048138 100 $a20202102d2016 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aImmunogenic Cell Death in Cancer: From Benchside Research to Bedside 210 $cFrontiers Media SA$d2016 215 $a1 online resource (145 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88919-838-3 330 $aClassically, anti-cancer therapies have always been applied with the primary aim of tumor debulking achieved through widespread induction of cancer cell death. While the role of host immune system is frequently considered as host protective in various (antigen-bearing) pathologies or infections yet in case of cancer overtime it was proposed that the host immune system either plays no role in therapeutic efficacy or plays a limited role that is therapeutically unemployable. The concept that the immune system is dispensable for the efficacy of anticancer therapies lingered on for a substantial amount of time; not only because evidence supporting the claim that anti-cancer immunity played a role were mainly contradictory, but also largely because it was considered acceptable (and sometimes still is) to test anticancer therapies in immunodeficient mice (i.e. SCID/athymic mice lacking adaptive immune system). This latter practice played a detrimental role in appreciating the role of anticancer immunity in cancer therapy. This scenario is epitomized by the fact that for a long time the very existence of cancer-associated antigens or cancer-associated 'danger signaling' remained controversial. However, over last several years this dogmatic view has been considerably modified. The existence of cancer-associated antigens and 'danger signaling' has been proven to be incontrovertible. These developments have together paved way for the establishment of the attractive concept of "immunogenic cell death" (ICD). It has been established that a restricted class of chemotherapeutics/targeted therapeutics, radiotherapy, photodynamic therapy and certain oncolytic viruses can induce a form of cancer cell death called ICD which is accompanied by spatiotemporally defined emission of danger signals. These danger signals along with other factors help cancer cells undergoing ICD to activate host innate immune cells, which in turn activate T cell-based immunity that helps eradicate live (or residual) surviving cancer cells. The emergence of ICD has been marred by some controversy. ICD has been criticized to be either experimental model or setting-specific or mostly a concept based on rodent studies that may have very limited implications for clinical application. However, in recent times it has emerged (through mainly retrospective or prognostic studies) that ICD can work in various human clinical settings hinting towards clinical applicability of ICD. However a widespread consensus on this issue is still transitional. In the current Research Topic we aimed to organize and intensify a discussion that strives to bring together the academic and clinical research community in order to provide a background to the current state-of-the-art in ICD associated bench-side research and to initiate fruitful discussions on present and future prospects of ICD translating towards the clinical, bedside reality. 517 $aImmunogenic Cell Death in Cancer 606 $aCell Death 606 $aApoptosis 606 $aMonitoring, Immunologic 606 $aGenes, Tumor Suppressor 606 $aImmunogenic Cell Death 606 $aNeoplasms 610 $aanti-tumor immunity 610 $aApoptosis 610 $acancer immunology 610 $acancer immunotherapy 610 $aCell Death 610 $aDAMPs 610 $adanger signals 610 $aimmunocontexture 610 $aimmunosurveillance 610 $anecroptosis 610 $apatient immunology 610 $aprognostic/predictive biomarker 615 2$aCell Death. 615 2$aApoptosis. 615 2$aMonitoring, Immunologic. 615 2$aGenes, Tumor Suppressor. 615 2$aImmunogenic Cell Death. 615 2$aNeoplasms. 700 $aAbhishek D. Garg$4auth$01331951 702 $aPatrizia Agostinis$4auth 906 $aBOOK 912 $a9910163538103321 996 $aImmunogenic Cell Death in Cancer: From Benchside Research to Bedside$93040695 997 $aUNINA